Watchlist Price Alert

MERCK Kommanditgesellscha... (MKGAF)

PNK: MKGAF · Real-Time Price · USD

142.95

2.80 (2.00%)

At close: May 07, 2025, 3:56 PM

2.00% (1D)

Bid	135.05
Market Cap	62.15B
Revenue (ttm)	21.16B
Net Income (ttm)	2.78B
EPS (ttm)	7.24
PE Ratio (ttm)	19.74
Forward PE	n/a
Analyst	n/a

Ask	144.13
Volume	7
Avg. Volume (20D)	720
Open	143.21
Previous Close	140.15
Day's Range	142.65 - 143.62
52-Week Range	118.05 - 200.56
Beta	0.64

About MKGAF

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MKGAF

Website n/a

Full Company Profile

News

2 weeks ago · proactiveinvestors.co.uk

Merck KGaA swoops for US group SpringWorks in $3.4bn deal

Germany's Merck KGaA has agreed to acquire US biotech firm SpringWorks Therapeutics for $3.9 billion in cash. The deal, announced on Monday, values SpringWorks at $47 a share and reflects an enterpris...

2 weeks ago · wsj.com

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.

2 weeks ago · reuters.com

Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks

German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug busi...

2 months ago · youtube.com

Resilience is part of our DNA, says Merck KGaA CEO

Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering prof...

2 months ago · seekingalpha.com

Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Florian Schraeder - Head of Investor Relations Belen Garijo - Group CEO Helene von Roeder - Group...

2 months ago · reuters.com

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.

3 months ago · reuters.com

Exclusive: Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say

Merck KGaA , the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter...